Peter Wirth

Peter Wirth is a Venture Partner with Quan Capital Management, a global venture capital company investing in the life sciences; Chairman of Syros Pharmaceuticals, Inc. (Nasdaq: SYRS), an oncology-focused biotechnology company, and a Director and Senior Advisor to Zai Lab Limited (Nasdaq: ZLAB), a Shanghai-based emerging biopharmaceutical company. From 2011 to 2014, Mr. Wirth was a founder, president and director of Lysosomal Therapeutics, Inc., a biotechnology company working on Parkinson’s disease.

From 1996 until its acquisition by Sanofi in 2011, Mr. Wirth was a senior executive at Genzyme Corporation, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. Prior to joining Genzyme, Mr. Wirth practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside general counsel for Genzyme as well as numerous other biopharmaceutical companies.

Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. He received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.